Tiziana Life Sciences completes Phase 2a INFORM-MS last patient visit for intranasal foralumab in na-SPMS

Bitget2026/09/21 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tiziana reported the last patient completed the final visit in its Phase 2a INFORM-MS trial of intranasal foralumab in na-SPMS.
Topline 12-week treatment results have not been presented yet; release is scheduled for October following a database lock this week.
The study is designed to show whether the therapy can safely reduce disease-related brain immune activity, with signals on disability and fatigue.
Participants can enter a six-month open-label extension, supporting longer-term safety and potential durability readouts.
Management pointed to expanded-access experience suggesting patients generally held steady or improved, setting expectations into the October data event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tiziana Life Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609210700OMX_____CNEWS_EN_GNW9830361_en) on September 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tiziana Life Sciences completes Phase 2a INFORM-MS last patient visit for intranasal foralumab in na-SPMS

You may also like

Crypto prices